Theravance Biopharma (NASDAQ:TBPH) Price Target Raised to $25.00 at BTIG Research

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) had its price objective boosted by equities researchers at BTIG Research from $24.00 to $25.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. BTIG Research's price target would suggest a potential upside of 120.95% from the company's current price.

A number of other equities analysts have also commented on TBPH. Wall Street Zen upgraded shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday, June 21st. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target for the company in a report on Tuesday, June 17th. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.60.

Theravance Biopharma Price Performance

Shares of NASDAQ:TBPH traded up $0.59 during trading on Friday, hitting $11.32. 107,341 shares of the company were exchanged, compared to its average volume of 269,016. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $11.82. The stock has a 50 day moving average of $9.94 and a 200 day moving average of $9.50. The company has a market cap of $565.75 million, a PE ratio of -9.54 and a beta of -0.09.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. The company had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. Sell-side analysts forecast that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 24,000 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $11.00, for a total value of $264,000.00. Following the completion of the sale, the senior vice president now owns 336,918 shares of the company's stock, valued at $3,706,098. This represents a 6.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

Hedge funds have recently made changes to their positions in the business. Nuveen LLC bought a new position in shares of Theravance Biopharma during the 1st quarter valued at $3,348,000. Newtyn Management LLC grew its stake in shares of Theravance Biopharma by 5.7% during the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock valued at $44,767,000 after buying an additional 258,337 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Theravance Biopharma by 121,993.7% during the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock valued at $1,554,000 after buying an additional 174,451 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Theravance Biopharma by 20.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock worth $5,211,000 after buying an additional 95,304 shares during the period. Finally, Jane Street Group LLC lifted its stake in shares of Theravance Biopharma by 169.2% in the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock valued at $1,258,000 after acquiring an additional 88,540 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.